Ketan Mehta

Ketan Mehta is the chief executive of Tris Pharma, a company involved in developing new pain management therapies. He has overseen the development of cebranopadol, a novel painkiller that activates specific opioid receptors with a lower risk of addiction compared to traditional opioids.